ICE vs NKTR · P/E 37, rev $7.28B vs rev $21.0M
Intercontinental Exchange Inc (ICE) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Intercontinental Exchange Inc (ICE) is a financial data & stock exchanges company listed on US.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported ICE revenue for 2026-06-30 was $7.28B. Net income was $2.37B. Revenue was up 98.5% from 2026-03-31 to 2026-06-30. ICE currently screens at market cap $103.55B and trailing P/E 37.3.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
ICE currently screens at market cap $103.55B and trailing P/E 37.3. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the ICE and NKTR stock pages for the full models.
Not investment advice.